Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
05 12 2020
Historique:
received: 11 02 2020
revised: 25 05 2020
accepted: 29 06 2020
pubmed: 17 9 2020
medline: 2 3 2021
entrez: 16 9 2020
Statut: ppublish

Résumé

Cortical superficial siderosis is an established haemorrhagic neuroimaging marker of cerebral amyloid angiopathy. In fact, cortical superficial siderosis is emerging as a strong independent risk factor for future lobar intracerebral haemorrhage. However, the underlying neuropathological correlates and pathophysiological mechanisms of cortical superficial siderosis remain elusive. Here we use an in vivo MRI, ex vivo MRI, histopathology approach to assess the neuropathological correlates and vascular pathology underlying cortical superficial siderosis. Fourteen autopsy cases with cerebral amyloid angiopathy (mean age at death 73 years, nine males) and three controls (mean age at death 91 years, one male) were included in the study. Intact formalin-fixed cerebral hemispheres were scanned on a 3 T MRI scanner. Cortical superficial siderosis was assessed on ex vivo gradient echo and turbo spin echo MRI sequences and compared to findings on available in vivo MRI. Subsequently, 11 representative areas in four cases with available in vivo MRI scans were sampled for histopathological verification of MRI-defined cortical superficial siderosis. In addition, samples were taken from predefined standard areas of the brain, blinded to MRI findings. Serial sections were stained for haematoxylin and eosin and Perls' Prussian blue, and immunohistochemistry was performed against amyloid-β and GFAP. Cortical superficial siderosis was present on ex vivo MRI in 8/14 cases (57%) and 0/3 controls (P = 0.072). Histopathologically, cortical superficial siderosis corresponded to iron-positive haemosiderin deposits in the subarachnoid space and superficial cortical layers, indicative of chronic bleeding events originating from the leptomeningeal vessels. Increased severity of cortical superficial siderosis was associated with upregulation of reactive astrocytes. Next, cortical superficial siderosis was assessed on a total of 65 Perls'-stained sections from MRI-targeted and untargeted sampling combined in cerebral amyloid angiopathy cases. Moderate-to-severe cortical superficial siderosis was associated with concentric splitting of the vessel wall (an advanced form of cerebral amyloid angiopathy-related vascular damage) in leptomeningeal vessels (P < 0.0001), but reduced cerebral amyloid angiopathy severity in cortical vessels (P = 0.048). In terms of secondary tissue injury, moderate-to-severe cortical superficial siderosis was associated with the presence of microinfarcts (P = 0.025), though not microbleeds (P = 0.973). Collectively, these data suggest that cortical superficial siderosis on MRI corresponds to iron-positive deposits in the superficial cortical layers, representing the chronic manifestation of bleeding episodes from leptomeningeal vessels. Cortical superficial siderosis appears to be the result of predominantly advanced cerebral amyloid angiopathy of the leptomeningeal vessels and may trigger secondary ischaemic injury in affected areas.

Identifiants

pubmed: 32935842
pii: 5906151
doi: 10.1093/brain/awaa266
pmc: PMC8453293
doi:

Substances chimiques

Amyloid beta-Peptides 0
GFAP protein, human 0
Glial Fibrillary Acidic Protein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3343-3351

Subventions

Organisme : NIA NIH HHS
ID : K99 AG059893
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG026484
Pays : United States

Informations de copyright

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Neurology. 2019 Jul 23;93(4):e358-e371
pubmed: 31243071
Neurology. 1993 Oct;43(10):2073-9
pubmed: 8413970
Stroke. 2018 Feb;49(2):491-497
pubmed: 29335334
Stroke. 2010 Oct;41(10 Suppl):S103-6
pubmed: 20876479
Am J Neurodegener Dis. 2014 Mar 28;3(1):19-32
pubmed: 24754000
Cerebrovasc Dis. 2013;36(3):245-6
pubmed: 24135538
Neurology. 2001 Feb 27;56(4):537-9
pubmed: 11222803
AJNR Am J Neuroradiol. 2008 Jan;29(1):184-6
pubmed: 17947366
Neurology. 2019 Dec 10;93(24):e2192-e2202
pubmed: 31732564
Neurology. 2013 Nov 5;81(19):1666-73
pubmed: 24107862
Ann Neurol. 2005 Oct;58(4):639-44
pubmed: 16178030
Neurology. 2013 Jul 16;81(3):292-300
pubmed: 23858411
Sci Transl Med. 2011 Jun 29;3(89):89ra57
pubmed: 21715678
Ann Neurol. 2019 Aug;86(2):279-292
pubmed: 31152566
Neurology. 2017 Nov 21;89(21):2136-2142
pubmed: 29070668
Cerebrovasc Dis. 2013;36(5-6):412-7
pubmed: 24281052
J Cereb Blood Flow Metab. 2018 Feb;38(2):225-229
pubmed: 29168672
Stroke. 2011 Mar;42(3):722-7
pubmed: 21212395
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
Neurology. 2019 Feb 26;92(9):e933-e943
pubmed: 30700595
Brain. 2017 Oct 1;140(10):2673-2690
pubmed: 28969382
Stroke. 2017 Dec;48(12):3210-3214
pubmed: 29070715
Neurol Genet. 2020 Mar 13;6(2):e411
pubmed: 32337337
Stroke. 1983 Nov-Dec;14(6):915-23
pubmed: 6658995
Brain. 2015 Aug;138(Pt 8):2126-39
pubmed: 26115675
Stroke. 2018 Oct;49(10):2330-2336
pubmed: 30355109
Alzheimers Dement. 2012 Jan;8(1):1-13
pubmed: 22265587
Am J Pathol. 1996 Jun;148(6):2083-95
pubmed: 8669492
J Neurol. 2019 Aug;266(8):1887-1896
pubmed: 31049727
Stroke. 2012 Sep;43(9):2324-30
pubmed: 22798323

Auteurs

Andreas Charidimou (A)

J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Boston Medical Center, Boston University, Boston, MA, USA.

Valentina Perosa (V)

J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Matthew P Frosch (MP)

Neuropathology Service, C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Ashley A Scherlek (AA)

MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA, USA.

Steven M Greenberg (SM)

J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Susanne J van Veluw (SJ)

J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH